RESUMEN
This study investigated the effects of co-administration of a commercial juice rich in vitamin C (Vit C) on the antimalarial efficacy of artemether-lumefantrine (AL) in Plasmodium berghei-infected mice. Fifty Balb/c mice were infected with Plasmodium berghei NK65 strain from a donor mouse. Parasitemia was established after 72 h. Animals were grouped into 6 (n = 10) and treated daily for 3 days with normal saline, chloroquine, artemether-lumefantrine (AL), AL plus 50% commercial juice (CJ), and AL plus 50% Vit C supplementation in drinks ad libitum, respectively. Body weight, parasitemia levels, and mean survival time were determined. Tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), nitrite, malondialdehyde, reduced glutathione (GSH), catalase, and superoxide dismutase (SOD) were determined in the serum and liver tissues. Spleen histopathological changes were determined by H&E staining. Parasitemia was cleared by administration of AL and was not affected by Vit C and CJ supplementation. Vit C significantly prevented body weight reduction in AL-treated mice. CJ and Vit C supplementation to AL-treated mice significantly improved survival proportion compared with AL alone animals. Vit C and CJ supplementation significantly improved reduction of TNF-α, IL-6, and malondialdehyde, and increased GSH, CAT, and SOD in AL-treated mice. Spleen cell degeneration and presence of malaria pigment were reduced in AL-treated animals. The results suggest that ad libitum co-administration of commercial juice and vitamin C with artemether-lumefantrine does not impair its antimalarial efficacy but rather improved antioxidant and anti-inflammatory effects in mice.
Asunto(s)
Antimaláricos , Malaria , Animales , Ratones , Antimaláricos/uso terapéutico , Antimaláricos/farmacología , Combinación Arteméter y Lumefantrina/farmacología , Combinación Arteméter y Lumefantrina/uso terapéutico , Plasmodium berghei , Arteméter/farmacología , Arteméter/uso terapéutico , Malaria/tratamiento farmacológico , Malaria/patología , Ácido Ascórbico/farmacología , Parasitemia/tratamiento farmacológico , Interleucina-6 , Factor de Necrosis Tumoral alfa , Superóxido Dismutasa , MalondialdehídoRESUMEN
In countries of sub-Saharan Africa, many children are admitted to hospital with severe forms of anaemia. The late hospital admissions of anaemic children contribute significantly to child morbidity and mortality in these countries. This qualitative study explores local health beliefs and traditional treatment practices that may hinder timely seeking of hospital care for anaemic children. In January of 2019, nine focus group discussions were conducted with 90 participants in rural communities of Malawi. The participants represented four groups of caregivers; mothers, fathers, grandmothers and grandfathers of children under the age of five. The Malawian medical landscape is comprised of formal and informal therapeutic alternatives-and this myriad of modalities is likely to complicate the healthcare choices of caregivers. When dealing with child illness, many participants reported how they would follow a step-by-step, 'multi-try' therapeutic pathway where a combination of biomedical and traditional treatment options were sought at varying time points depending on the perceived cause and severity of symptoms. The participants linked anaemia to naturalistic (malaria, poor nutrition and the local illnesses kakozi and kapamba), societal (the local illness msempho) and supernatural or personalistic (witchcraft and Satanism) causes. Most participants agreed that anaemia due to malaria and poor nutrition should be treated at hospital. As for local illnesses, many grandparents suggested herbal treatment offered by traditional healers, while the majority of parents would opt for hospital care. However, participants across all age groups claimed that anaemia caused by witchcraft and Satanism could only be dealt with by traditional healers or prayer, respectively. The multiple theories of anaemia causality combined with extensive use of and trust in traditional and complementary medicine may explain the frequent delay in admittance of anaemic children to hospital.
Asunto(s)
Anemia/patología , Cuidadores/psicología , Padre/psicología , Madres/psicología , Hechicería , Adulto , Escolaridad , Femenino , Grupos Focales , Humanos , Entrevistas como Asunto , Malaria/patología , Malaui , Masculino , Desnutrición/patología , Medicinas Tradicionales Africanas , Encuestas y CuestionariosRESUMEN
BACKGROUND: Micronutrients are minerals and vitamins and they are essential for normal physiological activities. The objectives of the study were to describe the progress and determinants of micronutrient levels and to assess the effects of micronutrients in the treatment outcome of kalazar. METHODS: A prospective cohort study design was used. The data were collected using patient interviews, measuring anthropometric indicators, and collecting laboratory samples. The blood samples were collected at five different periods during the leishmaniasis treatments: before starting anti-leishmaniasis treatments, in the first week, in the second week, in the third week, and in the 4th week of anti-leishmaniasis treatments. Descriptive statistics were used to describe the profile of patients and to compare the treatment success rate. The generalized estimating equation was used to identify the determinants of serum micronutrients. RESULTS: The mean age of the patients were 32.88 years [SD (standard deviation) ±15.95]. Male constitute 62.3% of the patients and problematic alcohol use was present in 11.5% of the patients. The serum zinc level of visceral leishmaniasis patients was affected by alcohol (B - 2.7 [95% CI: - 4.01 - -1.5]), DDS (B 9.75 [95% CI: 7.71-11.79]), family size (B -1.63 [95% CI: - 2.68 - -0.58]), HIV (B -2.95 [95% CI: - 4.97 - -0.92]), and sex (B - 1.28 [95% CI: - 2.5 - -0.07]). The serum iron level of visceral leishmaniasis patients was affected by alcohol (B 7.6 [95% CI: 5.86-9.35]), family size (B -5.14 [95% CI: - 7.01 - -3.28]), malaria (B -12.69 [95% CI: - 14.53 - -10.87]), Hookworm (- 4.48 [- 6.82 - -2.14]), chronic diseases (B -7.44 [95% CI: - 9.75 - -5.13]), and HIV (B -5.51 [95% CI: - 8.23 - -2.78]). The serum selenium level of visceral leishmaniasis patient was affected by HIV (B -18.1 [95% CI: - 20.63 - -15.58]) and family size (B -11.36 [95% CI: - 13.02 - -9.7]). The iodine level of visceral leishmaniasis patient was affected by HIV (B -38.02 [95% CI: - 41.98 - -34.06]), DDS (B 25 .84 [95% CI: 22.57-29.1]), smoking (B -12.34 [95% CI: - 15.98 - -8.7]), chronic illness (B -5.14 [95% CI: - 7.82 - -2.46]), and regular physical exercise (B 5.82 [95% CI: 0.39-11.26]). The serum vitamin D level of visceral leishmaniasis patient was affected by HIV (B -9.43 [95% CI: - 10.92 - -7.94]), DDS (B 16.24 [95% CI: 14.89-17.58]), malaria (B -0.61 [95% CI: - 3.37 - -3.37]), and family size (B -1.15 [95% CI: - 2.03 - -0.28]). The serum vitamin A level of visceral leishmaniasis patient was affected by residence (B 0.81 [95% CI: 0.08-1.54]), BMI (B 1.52 [95% CI: 0.42-2.6]), DDS (B 1.62 [95% CI: 0.36-2.88]), family size (B -5.03 [95% CI: - 5.83 - -4.22]), HIV (B -2.89 [95% CI: - 4.44 - -1.34]),MUAC (B 0.86 [95% CI: 0.52-1.21]), and age (B 0.09 [95% CI: 0.07-0.12]). CONCLUSION: The micronutrient levels of visceral leishmaniasis patients were significantly lower. The anti-leishmaniasis treatment did not increase the serum micronutrient level of the patients.
Asunto(s)
Antiprotozoarios/uso terapéutico , Leishmaniasis Visceral/tratamiento farmacológico , Micronutrientes/sangre , Adulto , Consumo de Bebidas Alcohólicas , Femenino , Infecciones por VIH/complicaciones , Infecciones por VIH/patología , Humanos , Entrevistas como Asunto , Leishmaniasis Visceral/complicaciones , Leishmaniasis Visceral/patología , Malaria/complicaciones , Malaria/patología , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Selenio/sangre , Zinc/sangreRESUMEN
Malaria is a worldwide serious-threatening infectious disease caused by Plasmodium and the parasite resistance to antimalarial drugs has confirmed a significant obstacle to novel therapeutic antimalarial drugs. In this article, we assessed the antioxidant and anti-inflammatory activity of nanoparticles prepared from Indigofera oblongifolia extract (AgNPs) against the infection with Plasmodium chabaudi caused in mice spleen. AgNPs could significantly suppress the parasitaemia caused by the parasite to approximately 98% on day 7 postinfection with P. chabaudi and could improve the histopathological induced spleen damage. Also, AgNPs were able to increase the capsule thickness of the infected mice spleen. In addition, the AgNPs functioned as an antioxidant agent that affects the change in glutathione, nitric oxide and catalase levels in the spleen. Moreover spleen IL1ß, IL-6 and TNF-α-mRNA expression was regulated by AgNPs administration to the infected mice. These results indicated the anti-oxidant and the anti-inflammatory protective role of AgNPs against P. chabaudi-induced spleen injury.
Asunto(s)
Antioxidantes/farmacología , Indigofera/metabolismo , Malaria/tratamiento farmacológico , Extractos Vegetales/farmacología , Plasmodium chabaudi/efectos de los fármacos , Plata/farmacología , Animales , Catalasa/metabolismo , Glutatión/metabolismo , Interleucina-1beta/análisis , Interleucina-6/análisis , Malaria/parasitología , Malaria/patología , Masculino , Nanopartículas del Metal , Ratones , Ratones Endogámicos C57BL , Óxido Nítrico/metabolismo , Parasitemia/tratamiento farmacológico , Parasitemia/patología , Bazo/parasitología , Factor de Necrosis Tumoral alfa/análisisRESUMEN
AIMS: Malaria in pregnancy (MiP) alters the expression of ATP-binding cassette efflux transporters in maternal and foetal tissues, as well as the placenta. Malaria induces oxidative stress, and pregnancy is associated with arginine deficiency. We hypothesized that reducing oxidative stress during MiP by supplementation with L-arginine, a NO precursor, would attenuate transcriptional changes in a second superfamily of transporters, solute carrier (SLC) transporters, and improve pregnancy outcomes. METHODS AND RESULTS: Pregnant BALB/c mice receiving L-arginine (1.2%) in water, or water alone, were infected with Plasmodium berghei ANKA on gestational day 13 and sacrificed on gestational day 19. Compared to controls, the mRNA of numerous SLC transporters was downregulated in maternal and foetal tissues, as well as in the placentas of infected mice. While supplementation with L-arginine did improve foetal viability, it did not improve the mRNA expression of oxidative stress markers, transporters nor other indices of foetal and maternal health. Moreover, amino acid uptake transporters were downregulated upon infection, which could potentially contribute to decreased foetal birthweight. CONCLUSIONS: Malaria in pregnancy significantly alters the expression of SLC transporters in maternal and foetal tissues as well as the placenta, regardless of L-arginine supplementation. Further studies to investigate methods of reducing oxidative stress in MiP are warranted.
Asunto(s)
Malaria/patología , Estrés Oxidativo/fisiología , Placenta/metabolismo , Plasmodium berghei , Proteínas Transportadoras de Solutos/biosíntesis , Animales , Arginina/farmacología , Transporte Biológico , Femenino , Viabilidad Fetal/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Embarazo , Proteínas Transportadoras de Solutos/genéticaRESUMEN
This study evaluated the hepatotoxic effects of artesunate (AS), artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) co-administration with ciprofloxacin (CIP) using animal model. Chloroquine sensitive Plasmodium berghei NK65 strain infected albino mice (120) were utilized for this study, carried out in three phases. Phase 1 comprised eleven groups treated with different doses of either AS, AL, ASAQ or CIP alone. Phase 2 consisted of nine groups treated with 7mg/kg of CIP combined with different doses of AS, AL, ASAQ. Phase 3 comprised ten groups treated with 14mg/kg of CIP (CIP2) with different doses of AS, AL, ASAQ. Seventy-two hours after administration of drugs, toxicity was determined by evaluating the effect of drugs on liver enzymes using spectrophotometer. Statistical analysis revealed that CIP alone significantly (P<0.05) reduced the levels of Aspartate Transaminase (AST) and Serum Alanine Transaminase (ALT) compared to AS, AL and ASAQ alone. Combination of different doses of AS, AL and ASAQ with 7mg/kg CIP significantly increased the level of AST and ALT while combination of AS, AL and ASAQ with 14mg/kg CIP significantly decreased AST and ALT levels. Care should be taken during the co-administration of low dose ciprofloxacin with artesunate, artemether-lumefantrine or artesunate-amodiaquine.
Asunto(s)
Antibacterianos/administración & dosificación , Antimaláricos/administración & dosificación , Ciprofloxacina/administración & dosificación , Malaria/tratamiento farmacológico , Malaria/patología , Plasmodium berghei , Animales , Antibacterianos/toxicidad , Antimaláricos/toxicidad , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Ciprofloxacina/toxicidad , Evaluación Preclínica de Medicamentos/métodos , Quimioterapia Combinada , Femenino , Masculino , Ratones , Plasmodium berghei/aislamiento & purificaciónRESUMEN
Currently, the most effective antimalarial is artemisinin, which is extracted from the leaves of medicinal herb Artemisia annua L. (A. annua). Previous studies showed that the complex chemical matrix of A. annua could enhance both the bioavailability and efficacy of artemisinin. The present study aims to evaluate the efficacy and pharmacokinetic properties of a combination therapy based on artemisinin and 3 components from A. annua with high content (arteannuin B, arteannuic acid, and scopoletin). In vivo antimalarial activity was assessed following a 4-day treatment in murine malaria models (Plasmodium yoelii and Plasmodium berghei). Results showed that a much sharper reduction in parasitemia (~93%) was found in combination therapy compared with pure artemisinin (~31%), indicating pharmacodynamic synergism occurring between artemisinin and arteannuin B, arteannuic acid, and scopoletin. Multiple-dose pharmacokinetics further demonstrated that combination therapy results in increased area under the curve (AUC0â∞ ), Cmax , and t1/2 by 3.78-, 3.47-, and 1.13-fold in healthy mice, respectively, and by 2.62-, 1.82-, and 1.22-fold in P. yoelii-infected mice, respectively. The calculated oral clearance of combination therapy in healthy and P. yoelii-infected mice was also reduced. These findings imply that specific components in A. annua might offer a possibility to develop new artemisinin-based natural combination therapy for malaria treatment.
Asunto(s)
Antimaláricos/uso terapéutico , Artemisia annua/química , Artemisininas/uso terapéutico , Malaria/tratamiento farmacológico , Extractos Vegetales/química , Animales , Antimaláricos/farmacología , Artemisininas/farmacología , Malaria/patología , Masculino , RatonesRESUMEN
Malaria is still a major health problem worldwide. This study aimed to investigate the hepatoprotective role of Indigofera oblongifolia leaf extracts (ILE) against mice hepatic injury induced by Plasmodium chabaudi. Female C57BL/6 mice were treated with 100â¯mg/kg of ILE after infection with erythrocytes parasitized by P. chabaudi. On day 7 post-infection, the extract improved the histological alteration induced by the parasite. This was evidenced by the decreased histological index induced by ILE. Moreover, ILE was able to increase the hepatic antioxidant capacity and could significantly improve the decrease in erythrocyte count and hemoglobin content in mice blood plasma due to infection. ILE was also able to upregulate the expression of 24 genes related to metabolism and of 3 genes related to the immune response. Furthermore, the extract was able to downregulate the expression of 35 genes related to metabolism and of 82 genes related to immune response. Moreover, the microarray study showed that ILE regulated the change in gene expression induced by the parasite. Among these genes, we quantified the expression of cd209f, cyp7a1, Hsd3b5, Sult2a3, Lcn2, CcI8, Nos2, and saa3-mRNAs. These genes were regulated by ILE. Therefore, our results revealed the protective role of Indigofera oblongifolia against hepatic injury induced by blood stage malaria.
Asunto(s)
Indigofera/química , Hígado/efectos de los fármacos , Hígado/metabolismo , Extractos Vegetales/farmacología , Transcriptoma/efectos de los fármacos , Transcriptoma/genética , Animales , Antioxidantes/metabolismo , Antioxidantes/farmacología , Modelos Animales de Enfermedad , Eritrocitos/parasitología , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/genética , Hígado/lesiones , Hígado/patología , Malaria/parasitología , Malaria/patología , Ratones , Ratones Endogámicos C57BL , Parasitemia , Extractos Vegetales/química , Hojas de la Planta/química , Plasmodium chabaudi/patogenicidad , ARN Mensajero/metabolismo , Regulación hacia ArribaRESUMEN
Artemisinin is one of the most widely prescribed drugs against malaria and has recently received increased attention because of its other potential biological effects. The aim of this review is to summarize recent discoveries of the pharmaceutical effects of artemisinin in basic science along with its mechanistic action, as well as the intriguing results of recent clinical studies, with a focus on its antitumor activity. Scientific evidence indicates that artemisinin exerts its biological activity by generating reactive oxygen species that damage the DNA, mitochondrial depolarization, and cell death. In the present article review, scientific evidence suggests that artemisinin is a potential therapeutic agent for various diseases. Thus, this review is expected to encourage interested scientists to conduct further preclinical and clinical studies to evaluate these biological activities.
Asunto(s)
Antiinfecciosos/farmacología , Antiinfecciosos/uso terapéutico , Artemisininas/farmacología , Artemisininas/uso terapéutico , Malaria/tratamiento farmacológico , Humanos , Malaria/patologíaRESUMEN
BACKGROUND: The root of Icacina senegalensis is used for the treatment of malaria and related conditions in southeastern Nigeria. METHODS: To establish its efficacy, the ethanolic root bark extract was investigated as antiplasmodial agent against Plasmodium berghei in mice. A 4-day suppressive test and the curative effect against established infection models of antiplasmodial studies were used. RESULTS: The root bark extract of I. senegalensis (50, 100, and 200 mg/kg) exhibited a significant (p<0.05) dose-dependent activity against the parasite based on suppressive and curative study. The antimalarial effect of I. senegalensis is compared with that of chloroquine (10 mg/kg), the standard drug. The ethanolic root bark extract also prolonged the survival time of infected mice. CONCLUSIONS: The results showed that the root bark extract possesses a potential antiplasmodial activity, which can be exploited for the possible development of new antimalarial agent.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria/tratamiento farmacológico , Corteza de la Planta , Extractos Vegetales/uso terapéutico , Plasmodium berghei/efectos de los fármacos , Animales , Antimaláricos/aislamiento & purificación , Antimaláricos/farmacología , Relación Dosis-Respuesta a Droga , Etanol/farmacología , Etanol/uso terapéutico , Femenino , Malaria/patología , Masculino , Ratones , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Plasmodium berghei/fisiologíaRESUMEN
The UV-vis spectra of isocorydine 1, norisocorydine 2 and boldine 3 were studied in 2% v/v acetonitrile, at constant ionic strength (0.1 M NaCl, 35 degree Celsius). The pK(a) values of isocorydine 1 and norisocorydine 2 were 11.75 and 12.07, respectively. Boldine 3 gave a pK(a) value of 9.16 and 10.44. All of the alkaloids 1-3 were stable at physiological pH; thereby all of them will not ionize, thus permitting the basic nitrogen to be protonated and accumulated within the acidic food vacuole of Plasmodium via pH trapping. Subsequently, acidic food vacuoles that have been neutralized by alkaloids would result in enhancement of the antiplasmodial activity. The alkaloids showed antiplasmodial activity against Plasmodium falciparum and antioxidant activities; DPPH radical scavenging, metal chelating and ferric reducing power. The antioxidant properties of the alkaloids under investigation revealed that in addition to the antiplasmodial activity, the alkaloids can also prevent oxidative damage. It can be prevented by binding free heme and neutralizing the electrons produced during the Plasmodium falciparum mediated haemoglobin destruction in the host. Slightly basic properties of the aforementioned alkaloids, along with their antioxidant activities, are advantageous in improving the suppression of malaria infection that cause less damage to the host.
Asunto(s)
Alcaloides/farmacología , Antimaláricos/farmacología , Malaria/tratamiento farmacológico , Extractos Vegetales/farmacología , Plasmodium falciparum/efectos de los fármacos , Alcaloides/química , Alcaloides/aislamiento & purificación , Antimaláricos/química , Antimaláricos/aislamiento & purificación , Antioxidantes/química , Antioxidantes/aislamiento & purificación , Antioxidantes/farmacología , Aporfinas/química , Aporfinas/farmacología , Humanos , Lauraceae/química , Malaria/parasitología , Malaria/patología , Estructura Molecular , Extractos Vegetales/química , Plasmodium falciparum/patogenicidadRESUMEN
CONTEXT: Solenostemon monostachyus P. Beauv (Lamiaceae) is an important herb used traditionally in the treatment of malaria, fever, and other diseases. OBJECTIVES: Antiplasmodial and antipyretic activities of S. monostachyus aerial extract were evaluated to ascertain the folkloric claim of its antimalarial and antipyretic activities. MATERIALS AND METHODS: The extract (75-225 mg/kg) and fractions (chloroform and aqueous; 150 mg/kg) of S. monostachyus were investigated for suppressive, prophylactic, and curative antiplasmodial activities against chloroquine-sensitive Plasmodium berghei infections in Swiss albino mice and for antipyretic activity against 2,4-dinitrophenol and yeast-induced pyrexia. Artesunate (5 mg/kg) and pyrimethamine (1.2 mg/kg) were used as positive controls for antiplasmodial models. Thin films made from tail blood of each mouse were used to assess the level of parasitaemia of the mice. RESULTS: The extract/fractions progressively reduced parasitaemia induced by chloroquine sensitive P. berghei infection in prophylactic (28.48-71.72%), suppressive (12.52-72.47%), and curative (22.4-82.34%) models in mice. These reductions were statistically significant (p < 0.01-0.001). They also improved significantly (p < 0.01-0.001) the mean survival time (MST) from 12.26 to 25.63 d relative to control (11.36 d). The activities of extract/fractions were incomparable with that of the standard drugs used (artesunate and pyrimethamine). The extract exerted prominent inhibition of pyrexia on dinitrophenol (87.33-90.11%, 5 h) and yeast (56.22-65.33, 5 h) induced pyrexia. Inhibition was significant (p < 0.05-0.001) from 3 to 5 h post-administration of extract and in a dose-dependent fashion. CONCLUSION: The plant may possess antiplasmodial and antipyretic effects which may in part be mediated through the chemical constituents of the plant.
Asunto(s)
Antimaláricos/uso terapéutico , Antipiréticos/uso terapéutico , Lamiaceae , Extractos Vegetales/uso terapéutico , Animales , Antimaláricos/aislamiento & purificación , Antipiréticos/aislamiento & purificación , Femenino , Malaria/tratamiento farmacológico , Malaria/patología , Masculino , Ratones , Componentes Aéreos de las Plantas , Extractos Vegetales/aislamiento & purificación , Plasmodium berghei/efectos de los fármacos , Plasmodium berghei/fisiología , RatasRESUMEN
Gleichenia truncata is a highland fern from the Gleicheniaceae family known for its traditional use among indigenous communities in Asia to treat fever. The scientific basis of its effect has yet to be documented. A yeast-based kinase assay conducted in our laboratory revealed that crude methanolic extract (CME) of G. truncata exhibited glycogen synthase kinase-3 (GSK3)-inhibitory activity. GSK3ß is now recognized to have a pivotal role in the regulation of inflammatory response during bacterial infections. We have also previously shown that lithium chloride (LiCl), a GSK3 inhibitor suppressed development of Plasmodium berghei in a murine model of malarial infection. The present study is aimed at evaluating G. truncata for its anti-malarial and anti-inflammatory effects using in vivo malarial and melioidosis infection models respectively. In a four-day suppressive test, intraperitoneal injections of up to 250 mg/kg body weight (bw) G. truncata CME into P.berghei-infected mice suppressed parasitaemia development by >60%. Intraperitoneal administration of 150 mg/kg bw G. truncata CME into Burkholderia pseudomallei-infected mice improved survivability by 44%. G. truncata CME lowered levels of pro-inflammatory cytokines (TNF-α, IFN-γ) in serum and organs of B. pseudomallei-infected mice. In both infections, increased phosphorylations (Ser9) of GSK3ß were detected in organ samples of animals administered with G. truncata CME compared to controls. Taken together, results from this study strongly suggest that the anti-malarial and anti-inflammatory effects elicited by G. truncata in part were mediated through inhibition of GSK3ß. The findings provide scientific basis for the ethnomedicinal use of this fern to treat inflammation-associated symptoms.
Asunto(s)
Antiinflamatorios/farmacología , Antimaláricos/farmacología , Glucógeno Sintasa Quinasa 3/antagonistas & inhibidores , Malaria/tratamiento farmacológico , Melioidosis/tratamiento farmacológico , Extractos Vegetales/farmacología , Tracheophyta/química , Estructuras Animales/química , Animales , Antiinflamatorios/aislamiento & purificación , Antimaláricos/aislamiento & purificación , Citocinas/análisis , Citocinas/sangre , Modelos Animales de Enfermedad , Inhibidores Enzimáticos/farmacología , Glucógeno Sintasa Quinasa 3 beta , Inyecciones Intraperitoneales , Malaria/patología , Melioidosis/patología , Ratones Endogámicos BALB C , Ratones Endogámicos ICR , Extractos Vegetales/aislamiento & purificación , Suero/química , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
Diverse dehydroxy-isotebuquine derivatives were prepared by using a five step synthetic sequence in good yields. All these new 4-aminoquinolines were evaluated as inhibitors of haemozoin formation, where most of them showed a significant inhibition value (% IHF >97). The best inhibitors were tested in vivo as potential antimalarials in mice infected with Plasmodium berghei ANKA chloroquine susceptible strain, three of them (11b, 11d and 11h) displayed an antimalarial activity comparable to that of chloroquine.
Asunto(s)
Aminoquinolinas/química , Antimaláricos/síntesis química , Hemoproteínas/antagonistas & inhibidores , Aminoquinolinas/farmacología , Aminoquinolinas/uso terapéutico , Animales , Antimaláricos/farmacología , Antimaláricos/uso terapéutico , Cloroquina/farmacología , Evaluación Preclínica de Medicamentos , Hemoproteínas/metabolismo , Malaria/tratamiento farmacológico , Malaria/patología , Malaria/veterinaria , Masculino , Ratones , Ratones Endogámicos BALB C , Plasmodium berghei/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
CONTEXT: The rising problem of resistance to present antimalarial drugs stresses the need to look for newer antiplasmodial components with effective modes of action. The roots of Berberis aristata DC. (Berberidaceae) are used in the traditional medicine for malaria in various parts of India. OBJECTIVE: The objective of this study was to evaluate antiplasmodial activity of B. aristata roots extract for the validation of its traditional medicinal use. MATERIAL AND METHODS: Aqueous root extract of Berberis aristata (AREBA) was screened for its in vitro as well as in vivo antiplasmodial activity against lethal rodent malaria parasite Plasmodium berghei NK65. In vitro activity was evaluated against schizont maturation of P. berghei using various concentrations ranging from 1 to 100 µg/mL. For in vivo studies, AREBA at the doses of 150, 250, 350, and 650 mg/kg/d was administered to P. berghei infected BALB/c mice orally for 4 consecutive days (D0-D3). RESULTS: AREBA showed in vitro antiplasmodial activity with an IC50 value of 40 µg/mL. In vivo studies demonstrated a variable dose-dependent chemosuppression with higher efficacy at lower doses. At a dose of 350 mg/kg/d, the suppressive and preventive activities were found to be 67.1% and 53.9%, respectively, followed by enhancing mean survival period up to 12.8 d for the curative assay versus 7.5 d for the untreated mice. DISCUSSION AND CONCLUSION: These results provide relevant scientific evidences for the traditional medicinal use of this plant as malaria remedy and further advocates the isolation and characterization of active antiplasmodial principle from this plant.
Asunto(s)
Antimaláricos/uso terapéutico , Berberis , Malaria/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Raíces de Plantas , Plasmodium berghei/efectos de los fármacos , Animales , Antimaláricos/aislamiento & purificación , Antimaláricos/farmacología , Relación Dosis-Respuesta a Droga , Femenino , Malaria/patología , Ratones , Ratones Endogámicos BALB C , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Plasmodium berghei/aislamiento & purificación , Agua/farmacologíaRESUMEN
BACKGROUND & OBJECTIVES: Artemisinin isolated from Artemisia annua is the most potent antimalarial against chloroquine resistant Plasmodium falciparum malaria. We previously reported that the ethanolic leaf extract of Artemisia vulgaris, an invasive weed and the only Artemisia species in Sri Lanka, possess both potent and safe antimalarial activity (in terms of antiparasitic properties) in a P. berghei murine malaria model. We report here a prototype study that investigated antidisease activities of A. vulgaris ethanolic leaf extract (AVELE) in a P. berghei ANKA murine malaria model that elicit pathogenesis similar to falciparum malaria. Profound thrombocytosis and thrombocytopenia in mice were detected in early-stage (Day 3), and at a later stage of infection (Day 6), respectively. Plasmodium berghei infected mice, 7 or 8 days post-infection reached end-stage disease with rapid drop in body temperature and usually die within 24 h, as a consequence of cerebral malaria. METHODS: Three doses of the AVELE (500, 750 and 1000 mg/kg) were used to assess antidisease activity of A. vulgaris in terms of survival, effects on thrombocyte related pathology and end-stage disease, antipyretic activity, and antinociception, using standard methodology. RESULTS: The 1000 mg/kg dose of AVELE significantly increased survival, reversed the profound thrombocytopenia/ thrombocytosis (p ≤0.01), altered the end-stage disease (p ≤0.05), and manifested significant antipyretic and antinociceptive (p ≤0.05) activities. INTERPRETATION & CONCLUSION: We conclude that a crude ethanolic leaf extract of A. vulgaris, showed potent antimalarial properties, in terms of antidisease activities; antipyretic activity, peripheral and central antinociception, increased survival, averted end-stage disease and reversed thrombocytopenia/thrombocytosis.
Asunto(s)
Antimaláricos/uso terapéutico , Artemisia/química , Malaria/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Hojas de la Planta/química , Animales , Antimaláricos/aislamiento & purificación , Malaria/complicaciones , Malaria/patología , Masculino , Ratones Endogámicos ICR , Extractos Vegetales/aislamiento & purificación , Análisis de Supervivencia , Trombocitopenia/tratamiento farmacológico , Trombocitosis/tratamiento farmacológicoRESUMEN
Hematological and antioxidant effects of the aqueous extract of fruiting bodies of Ganoderma lucidum were evaluated in Plasmodium berghei-infected mice. Extract was administered at doses of 100, 250, and 500 mg/kg body weight by an intragastric tube once daily for 14 d starting from the fourth day after parasite inoculation. At the end of treatment period, mice in each group were sacrificed and blood was collected for hematological and biochemical analyses. A significant (P<0.05) decrease was observed in serum malondialdehyde content with a corresponding significant (P<0.05) increase in superoxide dismutase, glutathione peroxidase, glutathione S-transferase, and glucose 6-phosphate dehydrogenase activities in the extract-treated groups compared to the infected but untreated group. The results obtained suggest that crude aqueous extract of G. lucidum fruiting bodies possesses potent antioxidant activity that protects hemoglobin against Plasmodium-induced oxidative damage. These findings seem to justify the use of the plant in traditional African and Chinese medicine as an anti-inflammatory and antimicrobial agent.
Asunto(s)
Antioxidantes/administración & dosificación , Células Sanguíneas/efectos de los fármacos , Mezclas Complejas/administración & dosificación , Malaria/tratamiento farmacológico , Malaria/patología , Oxidorreductasas/análisis , Reishi/química , Animales , Antioxidantes/aislamiento & purificación , Análisis Químico de la Sangre , Mezclas Complejas/aislamiento & purificación , Modelos Animales de Enfermedad , Masculino , RatonesRESUMEN
Various combinations of Nauclea latifolia root, Artocarpus altilis stem bark, Murraya koenigii leaf and Enantia chlorantha stem bark used in African ethnomedicine as decoctions for malaria and fevers, and combinations with standard drugs, were investigated for antiplasmodial activities using Plasmodium berghei berghei-infected mice. The respective prophylactic and curative ED50 values of 189.4 and 174.5 mg/kg for N. latifolia and chemosuppressive ED50 value of 227.2 mg/kg for A. altilis showed that they were the best antimalarial herbal drugs. A 1.6-fold increase of the survival time given by the negative control was elicited by M. koenigii, thereby confirming its curative activity. Pyrimethamine with an ED50 of 0.5 ± 0.1 mg/kg for the prophylactic, and chloroquine with ED50 = 2.2 ± 0.1 and 2.2 ± 0.0 mg/kg for the chemosuppressive and curative tests, respectively, were significantly (p < 0.05) more active. Co-administrations of N. latifolia with the standard drugs significantly reduced their prophylactic, chemosuppressive and curative actions, possibly increasing the parasites' resistance. Binary combinations of N. latifolia or M. koenigii with any of the other plants significantly increased the prophylactic and suppressive activities of their individual plants, respectively. Also, E. chlorantha with A. altilis or N. latifolia enhanced their respective prophylactic or curative activities, making these combinations most beneficial against malaria infections. Combinations of three and four extracts gave varied activities. Hence, the results justified the combinations of ethnomedicinal plants in antimalarial herbal remedies and showed the importance of the three in vivo models in establishing antimalarial activity.
Asunto(s)
Fiebre/tratamiento farmacológico , Malaria/tratamiento farmacológico , Medicina Tradicional , Plasmodium berghei/efectos de los fármacos , África , Animales , Antimaláricos/administración & dosificación , Antimaláricos/química , Artocarpus/química , Combinación de Medicamentos , Fiebre/parasitología , Fiebre/patología , Humanos , Malaria/parasitología , Malaria/patología , Ratones , Murraya/química , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Plasmodium berghei/patogenicidad , Rubiaceae/químicaRESUMEN
Plasmodium falciparum and P. vivax malaria parasites are now resistant, or showing signs of resistance, to most drugs used in therapy. Novel chemical entities that exhibit new mechanisms of antiplasmodial action are needed. New antimalarials that block transmission of Plasmodium spp. from humans to Anopheles mosquito vectors are key to malaria eradication efforts. Although P. vivax causes a considerable number of malaria cases, its importance has for long been neglected. Vivax malaria can cause severe manifestations and death; hence there is a need for P. vivax-directed research. Plants used in traditional medicine, namely Artemisia annua and Cinchona spp. are the sources of the antimalarial natural products artemisinin and quinine, respectively. Based on these compounds, semi-synthetic artemisinin-derivatives and synthetic quinoline antimalarials have been developed and are the most important drugs in the current therapeutic arsenal for combating malaria. In the Amazon region, where P. vivax predominates, there is a local tradition of using plant-derived preparations to treat malaria. Here, we review the current P. falciparum and P. vivax drug-sensitivity assays, focusing on challenges and perspectives of drug discovery for P. vivax, including tests against hypnozoites. We also present the latest findings of our group and others on the antiplasmodial and antimalarial chemical components from Amazonian plants that may be potential drug leads against malaria.
Asunto(s)
Antimaláricos/uso terapéutico , Descubrimiento de Drogas , Malaria/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Artemisia annua/química , Productos Biológicos/uso terapéutico , Cloroquina/uso terapéutico , Humanos , Malaria/parasitología , Malaria/patología , Plasmodium falciparum/patogenicidad , Quinina/uso terapéuticoRESUMEN
BACKGROUND: In the face of chronic and emerging resistance of parasites to currently available drugs and constant need for new anti-malarials, natural plant products have been the bastion of anti-malarials for thousands of years. Moreover natural plant products and their derivatives have traditionally been a common source of drugs, and represent more than 30% of the current pharmaceutical market. The present study shows evaluation of anti-malarial effects of compound conessine isolated from plant Holarrhena antidysenterica frequently used against malaria in the Garhwal region of north-west Himalaya. METHODS: In vitro anti-plasmodial activity of compound was assessed using schizont maturation and parasite lactate dehydrogenase (pLDH) assay. Cytotoxic activities of the examined compound were determined on L-6 cells of rat skeletal muscle myoblast. The four-day test for anti-malarial activity against a chloroquine-sensitive Plasmodium berghei NK65 strain in BALB/c mice was used for monitoring in vivo activity of compound. In liver and kidney function test, the activity of alkaline phosphatase (ALP) was examined by p-NPP method, bilirubin by Jendrassik and Grof method. The urea percentage was determined by modified Berthelot method and creatinine by alkaline picrate method in serum of mice using ENZOPAK/CHEMPAK reagent kits. RESULTS: Compound conessine showed in vitro anti-plasmodial activity with its IC50 value 1.9 µg/ml and 1.3 µg/ml using schizont maturation and pLDH assay respectively. The compound showed cytotoxity IC50= 14 µg/ml against L6 cells of rat skeletal muscle myoblast. The isolated compound from plant H. antidysenterica significantly reduced parasitaemia (at 10 mg/kg exhibited 88.95% parasite inhibition) in P. berghei-infected mice. Due to slightly toxic nature (cytotoxicity = 14), biochemical analysis (liver and kidney function test) of the serum from mice after administration of conessine were also observed. CONCLUSION: The present investigation demonstrates that the compound conessine exhibited substantial anti-malarial property. The isolated compound could be chemically modified to obtain a more potent chemical entity with improved characteristics against malaria.